GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daehan New Pharm Co Ltd (XKRX:054670) » Definitions » EV-to-EBIT

Daehan New Pharm Co (XKRX:054670) EV-to-EBIT : 5.37 (As of Jun. 22, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Daehan New Pharm Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Daehan New Pharm Co's Enterprise Value is ₩116,990 Mil. Daehan New Pharm Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩21,804 Mil. Therefore, Daehan New Pharm Co's EV-to-EBIT for today is 5.37.

The historical rank and industry rank for Daehan New Pharm Co's EV-to-EBIT or its related term are showing as below:

XKRX:054670' s EV-to-EBIT Range Over the Past 10 Years
Min: -1067.93   Med: 8.12   Max: 463.69
Current: 5.36

During the past 13 years, the highest EV-to-EBIT of Daehan New Pharm Co was 463.69. The lowest was -1067.93. And the median was 8.12.

XKRX:054670's EV-to-EBIT is ranked better than
88.32% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.09 vs XKRX:054670: 5.36

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Daehan New Pharm Co's Enterprise Value for the quarter that ended in Mar. 2024 was ₩125,271 Mil. Daehan New Pharm Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩21,804 Mil. Daehan New Pharm Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 17.41%.


Daehan New Pharm Co EV-to-EBIT Historical Data

The historical data trend for Daehan New Pharm Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daehan New Pharm Co EV-to-EBIT Chart

Daehan New Pharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.75 -16.72 6.84 3.55 6.23

Daehan New Pharm Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.97 4.22 4.43 6.23 5.75

Competitive Comparison of Daehan New Pharm Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Daehan New Pharm Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daehan New Pharm Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daehan New Pharm Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Daehan New Pharm Co's EV-to-EBIT falls into.



Daehan New Pharm Co EV-to-EBIT Calculation

Daehan New Pharm Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=116990.457/21804.211
=5.37

Daehan New Pharm Co's current Enterprise Value is ₩116,990 Mil.
Daehan New Pharm Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩21,804 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daehan New Pharm Co  (XKRX:054670) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Daehan New Pharm Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=21804.211/125271.368
=17.41 %

Daehan New Pharm Co's Enterprise Value for the quarter that ended in Mar. 2024 was ₩125,271 Mil.
Daehan New Pharm Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩21,804 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daehan New Pharm Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Daehan New Pharm Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Daehan New Pharm Co (XKRX:054670) Business Description

Traded in Other Exchanges
N/A
Address
1062-4 Namhyeon-dong, Gwanak-gu, Seoul, KOR, 137-851
Daehan New Pharm Co Ltd is a South Korea based company operating in the pharmaceutical sector. It is engaged in producing pharmaceutical products, animal health and nutrition, and bio products. The pharmaceutical products are tertan tab, amloc tab, tarocin SR tab, NP star tab and others. The animal health and nutrition products are starvac, pigcoc for calves, ocean doctor, and others. The bio range of the products by the group are CELRENA serum-free, BMPro serum-free, BMPro-V serum-free, ALyS505NK-EX serum-free and others.

Daehan New Pharm Co (XKRX:054670) Headlines

No Headlines